According to the International Ki67 in Breast Cancer Working Group recommendations, a Ki67 threshold of 30% or greater could be used to proceed with chemotherapy without the need for more expensive commercial multi-parameter gene-expression assays [27]. This evidence concerns the gene MKI67 and breast cancer.